Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up After Better-Than-Expected Earnings

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s share price gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $1.94, but opened at $2.01. Autolus Therapeutics shares last traded at $1.92, with a volume of 220,321 shares traded.

The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.98 million.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AUTL shares. Wells Fargo & Company lowered their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday. Needham & Company LLC reissued a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $9.52.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AUTL. FMR LLC grew its holdings in Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company's stock worth $64,519,000 after acquiring an additional 5,478,706 shares during the period. Capstone Investment Advisors LLC bought a new position in shares of Autolus Therapeutics during the 3rd quarter worth about $51,000. Bellevue Group AG grew its stake in shares of Autolus Therapeutics by 27.7% in the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company's stock valued at $151,000 after buying an additional 9,000 shares during the period. Erste Asset Management GmbH acquired a new position in Autolus Therapeutics during the 3rd quarter worth approximately $708,000. Finally, HighVista Strategies LLC boosted its holdings in Autolus Therapeutics by 2.7% in the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company's stock worth $1,935,000 after acquiring an additional 14,204 shares in the last quarter. Institutional investors own 72.83% of the company's stock.

Remove Ads

Autolus Therapeutics Price Performance

The firm has a market cap of $455.02 million, a P/E ratio of -1.41 and a beta of 2.07. The firm has a fifty day simple moving average of $2.01 and a 200-day simple moving average of $2.88.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.